Skip to main content

Circulating microRNAs as novel biomarkers for platelet activation.

Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King A, Kirkby NS, Crosby-Nwaobi R, Prokopi M, Drozdov I, Langley SR, Sivaprasad S, Markus HS, Mitchell JA, Warner TD, Kiechl S, Mayr M

Publication: Circ Res (2013) • Vol 112 • Page 595-600PMID: 23283721View on PubMed

Purpose

The purpose of this paper was to identify platelet (Plt) specific microRNA (miRNA, miR) and to determine the effects of treatment with antiplatelet therapy on miRNA expression.

Conclusion

Of the 377 miRNA assayed, miR-223 had the highest expression in Plts and Plt microparticles (PMP) and was the most differentially expressed between platelet-rich plasma (PRP) and platelet-poor plasma (PPP) or serum. In addition to inhibiting Plt aggregation, treatment of patients with antiplatelet therapy resulted in declines in the levels of 16 of the 95 assayed miRNA in healthy patients and 19 of the 90 assayed miRNA in patients with symptomatic carotid atherosclerosis. Reductions in miR-106a, miR-126, miR-150, miR-191, and miR-223 were observed in response to antiplatelet therapy in both healthy patients and those with symptomatic carotid atherosclerosis. Importantly, levels of the frequently used control, U6, were significantly lower after healthy individuals were treated for 1 week with prasugrel alone and after a second week of treatment with both prasugrel and 75 mg aspirin, but returned to baseline after the third week of treatment.

Studies (2)

Purpose

The purpose of this study was to compare miRNA expression in Plts, PMP, PPP, PRP and serum and to identify a miRNA marker for Plts in healthy individuals and patients with type II diabetes. PPP, PRP and serum were obtained from 3 healthy individuals and serum and PPP were obtained from 19 patients with type II diabetes. miRNA was extracted using the miRNeasy kit and quantified by real-time qPCR using TaqMan cards.

Summary of Findings

Of the 377 miRNAs assessed, 136 miRNA were expressed in serum, PPP, and PRP, 31 were expressed in PPP and PRP, 7 were expressed in both serum and PRP, 96 were specific to PRP, 7 were specific to PPP and 1 just was specific to serum. Principal component analysis revealed that the majority of miRNAs were detected in PRP. The authors identified miR-223 as being the most differentially expressed miRNA between PRP, and PPP and serum in both healthy individuals and those diagnosed with diabetes, as it had the highest expression in Plts and PMP.

  • Biospecimens

    FluidPlasma
    FluidSerum
  • Preservation Types

    None (Fresh)
  • Diagnoses

    Normal
    Diabetes Type 2
  • Platforms

    RNALow density array
    RNAReal-time qRT-PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Healthy
    Type II diabetes
    Biospecimen Aliquots and ComponentsBlood and blood products
    Microparticles
    Plasma
    Platelet-poor plasma
    Platelet-rich plasma
    Platelets